DAWN - CIK 0001845337
Day One Biopharmaceuticals, Inc. (DAWN) reported net income of -$107.32B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$107.32B | -12.4% |
| FY 2024 | -$95.50B | +49.5% |
| FY 2023 | -$188.92B | -32.9% |
| FY 2022 | -$142.18B | -95.4% |
| FY 2021 | -$72.75B | -179508.5% |
| FY 2020 | -$40.51M | -220.6% |
| FY 2019 | -$12.63M | - |
Day One Biopharmaceuticals, Inc. (DAWN) reported net income of -$107.32B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Day One Biopharmaceuticals, Inc.'s net income declined from -$12.63M to -$107.32B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.